| Autor: |
Jun Zhu, Xiaonan Hong, Yu Qin Song, Brendan Hodkinson, Sriram Balasubramanian, Songbai Wang, Qingyuan Zhang, Yuankai Shi, Huiqiang Huang, Huilai Zhang, Yan Zhu, Stephen Martin Shreeve, Steven Sun, Ze Wang, Xiaocan Wang, Yue Fan, Wyndham Wilson, Jessica Vermeulen |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
eJHaem, Vol 3, Iss 4, Pp 1154-1164 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2688-6146 |
| DOI: |
10.1002/jha2.517 |
| Popis: |
Abstract In this post hoc subgroup analysis of 200 patients enrolled in China from the phase III PHOENIX trial (N = 838, NCT01855750), addition of ibrutinib to rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) did not improve event‐free survival (EFS) versus placebo+R‐CHOP in the intent‐to‐treat (ITT; n = 200, hazard ratio [HR] = 0.83, 95% confidence interval [CI]: 0·509–1.349; p = 0.4495) or activated B‐cell‐like (ABC; n = 141 [based on available gene‐expression profiling data], HR = 0.86, 95% CI: 0.467–1.570; p = 0.6160) subpopulations. However, ibrutinib+R‐CHOP improved EFS (HR = 0·50, 95% CI: 0.251–1.003) and progression‐free survival (PFS; HR = 0.48, 95% CI: 0.228–1.009) versus placebo+R‐CHOP in patients aged |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text